{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T09:32:28Z","timestamp":1794735148658,"version":"4.9.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS112350"],"award-info":[{"award-number":["R01 NS112350"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS112308"],"award-info":[{"award-number":["R01 NS112308"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuropharm.2025.110625","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:05:36Z","timestamp":1754438736000},"page":"110625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Brain-invading monocytes promote seizure-associated cognitive deficits and neurodegeneration"],"prefix":"10.1016","volume":"279","author":[{"given":"Soheila","family":"Pourkhodadad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7148-1700","authenticated-orcid":false,"given":"Wenyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7128-4520","authenticated-orcid":false,"given":"Raymond","family":"Dingledine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-1098","authenticated-orcid":false,"given":"Nicholas H.","family":"Varvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib1","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/s41598-023-32752-9","article-title":"Pharmacological inhibition of the inflammatory receptor CCR2 relieves the early deleterious consequences of status epilepticus","volume":"13","author":"Aleman-Ruiz","year":"2023","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110625_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99364","article-title":"Targeting inflammatory monocytes in sepsis-associated encephalopathy and long-term cognitive impairment","volume":"3","author":"Andonegui","year":"2018","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110625_bib3","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1161\/01.STR.0000033932.34467.97","article-title":"Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats","volume":"33","author":"Aoki","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2025.110625_bib4","article-title":"The oscillatory basis of working memory function and dysfunction in epilepsy","volume":"14","author":"Arski","year":"2020","journal-title":"Front. Hum. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110625_bib5","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/STROKEAHA.109.570515","article-title":"Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9","volume":"41","author":"Barr","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2025.110625_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.phrs.2016.03.003","article-title":"Addressing the burden of epilepsy: many unmet needs","volume":"107","author":"Beghi","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1474-4422(18)30412-5","article-title":"Treatment of epilepsy in light of the Most recent advances","volume":"18","author":"Beghi","year":"2019","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110625_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrneurol.2011.3","article-title":"The neurobiology of cognitive disorders in temporal lobe epilepsy","volume":"7","author":"Bell","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110625_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1523\/JNEUROSCI.22-02-00515.2002","article-title":"Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice","volume":"22","author":"Bondolfi","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110625_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.615802","article-title":"Multiple disruptions of glial-neuronal networks in epileptogenesis that follows prolonged febrile seizures","volume":"12","author":"Brennan","year":"2021","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110625_bib11","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.4049\/jimmunol.175.8.5370","article-title":"Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344","volume":"175","author":"Brodmerkel","year":"2005","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110625_bib12","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1111\/epi.14550","article-title":"Activation of the innate immune system is evident throughout epileptogenesis and is associated with blood-brain barrier dysfunction and seizure progression","volume":"59","author":"Broekaart","year":"2018","journal-title":"Epilepsia"},{"issue":"Suppl. 4","key":"10.1016\/j.neuropharm.2025.110625_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/epi.12298","article-title":"Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy","volume":"54","author":"Brooks-Kayal","year":"2013","journal-title":"Epilepsia"},{"issue":"6704","key":"10.1016\/j.neuropharm.2025.110625_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/27351","article-title":"Neuron loss in APP transgenic mice","volume":"395","author":"Calhoun","year":"1998","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110625_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-Year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"6553","key":"10.1016\/j.neuropharm.2025.110625_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf7844","article-title":"Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma","volume":"373","author":"Cugurra","year":"2021","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110625_bib17","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/JVI.02747-12","article-title":"Infiltrating macrophages are key to the development of seizures following virus infection","volume":"87","author":"Cusick","year":"2013","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110625_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nprot.2006.170","article-title":"Assessing nest building in mice","volume":"1","author":"Deacon","year":"2006","journal-title":"Nat. Protoc."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110625_bib19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s13365-018-0636-2","article-title":"The immune response to picornavirus infection and the effect of immune manipulation on acute seizures","volume":"24","author":"DePaula-Silva","year":"2018","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.neuropharm.2025.110625_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-94-017-8914-1_9","article-title":"When and how do seizures kill neurons, and is cell death relevant to epileptogenesis?","volume":"813","author":"Dingledine","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2025.110625_bib21","series-title":"Jasper\u2019s Basic Mechan Epilepsies","article-title":"Neuroinflammation in epilepsy: cellular and molecular mechanisms","author":"Dingledine","year":"2024"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.expneurol.2008.10.003","article-title":"Cognitive dysfunction after experimental febrile seizures","volume":"215","author":"Dube","year":"2009","journal-title":"Exp. Neurol."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110625_bib23","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/glia.23616","article-title":"Microglial proliferation and monocyte infiltration contribute to microgliosis following status epilepticus","volume":"67","author":"Feng","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110625_bib24","series-title":"Mouse Brain in Stereotaxic Coordinates","author":"Franklin","year":"1996"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/mol.115.098202","article-title":"EP2 receptor signaling regulates microglia death","volume":"88","author":"Fu","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110625_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5698\/1535-7511-16.3.187","article-title":"2014 epilepsy benchmarks area II: prevent epilepsy and its progression","volume":"16","author":"Galanopoulou","year":"2016","journal-title":"Epilepsy Curr."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110625_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5698\/1535-7511-16.3.198","article-title":"2014 epilepsy benchmarks area IV: limit or prevent adverse consequence of seizures and their treatment across the lifespan","volume":"16","author":"Goldman","year":"2016","journal-title":"Epilepsy Curr."},{"issue":"Suppl. 8","key":"10.1016\/j.neuropharm.2025.110625_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1528-1167.2007.01360.x","article-title":"Cognitive outcome of status epilepticus in adults","volume":"48","author":"Helmstaedter","year":"2007","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110625_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","article-title":"Neuroinflammation in alzheimer disease","volume":"25","author":"Heneka","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110625_bib30","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1528-1157.1999.tb00845.x","article-title":"Cognitive functions after pilocarpine-induced status epilepticus: changes during silent period precede appearance of spontaneous recurrent seizures","volume":"40","author":"Hort","year":"1999","journal-title":"Epilepsia"},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2025.110625_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/brain\/awl317","article-title":"TGF-Beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis","volume":"130","author":"Ivens","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110625_bib32","article-title":"Inhibition of the prostaglandin EP2 receptor prevents long-term cognitive impairment in a model of systemic inflammation","volume":"8","author":"Jiang","year":"2020","journal-title":"Brain Behav Immun Health"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110625_bib33","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1073\/pnas.1120195109","article-title":"Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2","volume":"109","author":"Jiang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110625_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nbd.2014.12.032","article-title":"Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus","volume":"76","author":"Jiang","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110625_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.sjpain.2012.10.003","article-title":"Evaluation of a novel chemokine receptor 2 (CCR2)-Antagonist in painful diabetic polyneuropathy","volume":"4","author":"Kalliomaki","year":"2013","journal-title":"Scand J Pain"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110625_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","article-title":"Management of psychiatric and neurological comorbidities in epilepsy","volume":"12","author":"Kanner","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110625_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2017.03.009","article-title":"Long-term outcome of refractory status epilepticus in adults: a retrospective population-based study","volume":"133","author":"Kantanen","year":"2017","journal-title":"Epilepsy Res."},{"issue":"38","key":"10.1016\/j.neuropharm.2025.110625_bib38","doi-asserted-by":"crossref","first-page":"E8929","DOI":"10.1073\/pnas.1806754115","article-title":"Chemokine receptors CCR2 and CX3CR1 regulate viral encephalitis-induced hippocampal damage but not seizures","volume":"115","author":"Kaufer","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110625_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199746545.003.0072","article-title":"Cognitive and behavioral comorbidities of epilepsy","author":"Kleen","year":"2012","journal-title":"Jasper's Basic Mechan Epilepsies"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ncl.2015.08.008","article-title":"Treatment of cognitive deficits in epilepsy","volume":"34","author":"Leeman-Markowski","year":"2016","journal-title":"Neurol. Clin."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110625_bib41","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1097\/CCM.0b013e3181f859a6","article-title":"Functional outcome after convulsive status epilepticus","volume":"38","author":"Legriel","year":"2010","journal-title":"Crit. Care Med."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110625_bib42","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/j.1528-1167.2012.03584.x","article-title":"Reduction in delayed mortality and subtle improvement in retrograde memory performance in pilocarpine-treated mice with conditional neuronal deletion of cyclooxygenase-2 gene","volume":"53","author":"Levin","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2025.110625_bib43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neurobiolaging.2023.06.001","article-title":"Cognition's dependence on functional network integrity with age is conditional on structural network integrity","volume":"129","author":"Liu","year":"2023","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110625_bib44","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3988\/jcn.2021.17.2.176","article-title":"Systematic literature review of psychiatric comorbidities in adults with epilepsy","volume":"17","author":"Lu","year":"2021","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110625_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107459","article-title":"Epidemiology of status epilepticus in the United States: a systematic review","volume":"112","author":"Lu","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eplepsyres.2005.09.023","article-title":"Cognitive and memory effects of the new antiepileptic drugs","volume":"68","author":"Meador","year":"2006","journal-title":"Epilepsy Res."},{"issue":"7844","key":"10.1016\/j.neuropharm.2025.110625_bib47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-020-03160-0","article-title":"Restoring metabolism of myeloid cells reverses cognitive decline in ageing","volume":"590","author":"Minhas","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110625_bib48","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1007\/s12035-018-1230-6","article-title":"Perampanel but not amantadine prevents behavioral alterations and epileptogenesis in pilocarpine rat model of status epilepticus","volume":"56","author":"Mohammad","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110625_bib49","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/CON.0000000000001123","article-title":"Neuropsychiatric and cognitive comorbidities in epilepsy","volume":"28","author":"Mula","year":"2022","journal-title":"Continuum"},{"issue":"Suppl. 5","key":"10.1016\/j.neuropharm.2025.110625_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1167.2008.01631.x","article-title":"Persistent hippocampal neurogenesis and epilepsy","volume":"49","author":"Parent","year":"2008","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110625_bib51","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1523\/JNEUROSCI.22-08-03174.2002","article-title":"Prolonged seizures increase proliferating neuroblasts in the adult rat subventricular zone-olfactory bulb pathway","volume":"22","author":"Parent","year":"2002","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110625_bib52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3988\/jcn.2008.4.3.99","article-title":"Cognitive effects of antiepileptic drugs","volume":"4","author":"Park","year":"2008","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110625_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2018.08.020","article-title":"Role of inflammation in epilepsy and neurobehavioral comorbidities: implication for therapy","volume":"837","author":"Paudel","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110625_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/ane.12898","article-title":"Cognitive dysfunction after generalized tonic-clonic status epilepticus in adults","volume":"137","author":"Power","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2025.110625_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.eplepsyres.2017.11.014","article-title":"Cognitive function after status epilepticus versus after multiple generalized tonic-clonic seizures","volume":"140","author":"Power","year":"2018","journal-title":"Epilepsy Res."},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110625_bib56","doi-asserted-by":"crossref","first-page":"9293","DOI":"10.1074\/jbc.M113.455816","article-title":"EP2 receptor signaling pathways regulate classical activation of microglia","volume":"288","author":"Quan","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110625_bib57","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s13311-020-00969-5","article-title":"A novel second-generation EP2 receptor antagonist reduces neuroinflammation and gliosis after status epilepticus in rats","volume":"18","author":"Rojas","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2025.110625_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neuropharm.2015.01.017","article-title":"Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus","volume":"93","author":"Rojas","year":"2015","journal-title":"Neuropharmacology"},{"issue":"Pt A","key":"10.1016\/j.neuropharm.2025.110625_bib59","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neuropharm.2016.07.028","article-title":"Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats","volume":"110","author":"Rojas","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/epi.12461","article-title":"Cyclooxygenase-2 in epilepsy","volume":"55","author":"Rojas","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2025.110625_bib61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neuro.2020.12.010","article-title":"Comparison of neuropathology in rats following status epilepticus induced by diisopropylfluorophosphate and soman","volume":"83","author":"Rojas","year":"2021","journal-title":"Neurotoxicology"},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2025.110625_bib62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1528-1167.2007.01065.x","article-title":"Relevance of seizure-induced neurogenesis in animal models of epilepsy to the etiology of temporal lobe epilepsy","volume":"48","author":"Scharfman","year":"2007","journal-title":"Epilepsia"},{"issue":"3\u20134","key":"10.1016\/j.neuropharm.2025.110625_bib63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/neu.2022.0033","article-title":"Ccr2 gene ablation does not influence seizure susceptibility, tissue damage, or cellular inflammation after murine pediatric traumatic brain injury","volume":"40","author":"Sharma","year":"2023","journal-title":"J. Neurotrauma"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib64","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-brain barrier: from physiology to disease and back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"issue":"33","key":"10.1016\/j.neuropharm.2025.110625_bib65","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1523\/JNEUROSCI.0315-17.2017","article-title":"Chemokine CCL2-CCR2 signaling induces neuronal cell death via STAT3 activation and IL-1beta production after status epilepticus","volume":"37","author":"Tian","year":"2017","journal-title":"J. Neurosci."},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2025.110625_bib66","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/brain\/awl318","article-title":"Blood-brain barrier leakage May lead to progression of temporal lobe epilepsy","volume":"130","author":"van Vliet","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110625_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109356","article-title":"Preclinical development of an EP2 antagonist for post-seizure cognitive deficits","volume":"224","author":"Varvel","year":"2023","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110625_bib68","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1523\/JNEUROSCI.2040-20.2020","article-title":"Peripheral myeloid cell EP2 activation contributes to the deleterious consequences of status epilepticus","volume":"41","author":"Varvel","year":"2021","journal-title":"J. Neurosci."},{"issue":"38","key":"10.1016\/j.neuropharm.2025.110625_bib69","doi-asserted-by":"crossref","first-page":"E5665","DOI":"10.1073\/pnas.1604263113","article-title":"Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus","volume":"113","author":"Varvel","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110625_bib70","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nbd.2017.12.001","article-title":"Macrophage depletion by liposome-encapsulated clodronate suppresses seizures but not hippocampal damage after acute viral encephalitis","volume":"110","author":"Waltl","year":"2018","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110625_bib71","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0047-15.2015","article-title":"Cognitive deficits, changes in synaptic function, and brain pathology in a mouse model of normal Aging(1,2,3)","volume":"2","author":"Weber","year":"2015","journal-title":"eNeuro"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110625_bib72","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0197-4580(93)90112-O","article-title":"New stereological methods for counting neurons","volume":"14","author":"West","year":"1993","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2025.110625_bib73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.seizure.2015.01.018","article-title":"Cognition in the early stages of adult epilepsy","volume":"26","author":"Witt","year":"2015","journal-title":"Seizure"},{"issue":"24","key":"10.1016\/j.neuropharm.2025.110625_bib74","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1016\/j.bmcl.2010.10.020","article-title":"Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2","volume":"20","author":"Xue","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1759-1961.2011.00024.x","article-title":"Role of CCR2 in immunobiology and neurobiology","volume":"3","author":"Yamasaki","year":"2012","journal-title":"Clin. Experi. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110625_bib76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s42466-021-00161-w","article-title":"Seizures and epilepsy in patients with ischaemic stroke","volume":"3","author":"Zollner","year":"2021","journal-title":"Neurol Res. Pract."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:19:16Z","timestamp":1780028356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825003338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":76,"alternative-id":["S0028390825003338"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110625","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain-invading monocytes promote seizure-associated cognitive deficits and neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110625"}}